Christopher Sikes-Keilp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christopher Sikes-Keilp has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- David R. Rubinow
Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, USA
2 shared publications - Angel V. Peterchev
Duke University
1 shared publication - Dana M. Lapato
Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University
1 shared publication - Elizabeth Andersen
Department of Psychiatry, University of North Carolina at Chapel Hill, 2218 Nelson Hwy, Suite 1, Chapel Hill, NC, 27517, United States of America
1 shared publication Elizabeth D. Wilson
The University of North Carolina at Chapel Hill
1 shared publication- Elyssa C. Feuer
University of Toledo College of Medicine
1 shared publication
Latest Publications
- Open Access
Neuron-Enriched Extracellular Vesicle MicroRNAs Reflect Hormone-Sensitive Neural Pathway Changes from Early to Late Perimenopause
The menopausal transition represents a major neuroendocrine shift marked by declining estradiol and progesterone, rising follicle-stimulating hormone, and increased vulnerability to cognitive and affective symptoms. Despite extensive evidence of hormone-related neural changes, few biomarkers directly index hormone-sensitive neuronal adaptations in vivo . Neuron-enriched extracellular vesicles (nEVs) isolated from blood provide a minimally invasive window into central nervous system (CNS) biology by carrying microRNAs (miRNAs) linked to neuronal regulatory processes. This pilot study tested whether L1 cell adhesion molecule (L1CAM)–positive nEV miRNA profiles differ between early (STRAW stage − 2; n = 22) and late (STRAW stage − 1; n = 24) perimenopause. A pooled discovery screen of 179 miRNAs identified 10 candidates with substantial fold-change differences between groups; these were then quantified at the individual level using qPCR. Linear mixed-effects models showed a significant main effect of STRAW stage, with late perimenopause associated with higher ΔCq values (lower overall expression) across the miRNA panel. The miRNA x STRAW stage interaction was not significant, indicating a coordinated shift across the measured miRNAs rather than miRNA-specific regulation. No evidence of an association between nEV miRNA expression and current estradiol levels or menopausal symptom severity was observed. Bioinformatic analysis of predicted mRNA targets identified significant enrichment of the gonadotropin-releasing hormone (GnRH) receptor pathway, along with related growth factor, immune, and intracellular signaling pathways, with preferential expression in brain-relevant tissues. These findings are consistent with stage-related differences in hormone-sensitive neuronal regulatory processes across the transition.
Open AccessNeuron-Enriched Extracellular Vesicle MicroRNAs Reflect Hormone-Sensitive Neural Pathway Changes from Early to Late Perimenopause
The menopausal transition represents a major neuroendocrine shift marked by declining estradiol and progesterone, rising follicle-stimulating hormone, and increased vulnerability to cognitive and affective symptoms. Despite extensive evidence of hormone-related neural changes, few biomarkers directly index hormone-sensitive neuronal adaptations in vivo . Neuron-enriched extracellular vesicles (nEVs) isolated from blood provide a minimally invasive window into central nervous system (CNS) biology by carrying microRNAs (miRNAs) linked to neuronal regulatory processes. This pilot study tested whether L1 cell adhesion molecule (L1CAM)–positive nEV miRNA profiles differ between early (STRAW stage − 2; n = 22) and late (STRAW stage − 1; n = 24) perimenopause. A pooled discovery screen of 179 miRNAs identified 10 candidates with substantial fold-change differences between groups; these were then quantified at the individual level using qPCR. Linear mixed-effects models showed a significant main effect of STRAW stage, with late perimenopause associated with higher ΔCq values (lower overall expression) across the miRNA panel. The miRNA x STRAW stage interaction was not significant, indicating a coordinated shift across the measured miRNAs rather than miRNA-specific regulation. No evidence of an association between nEV miRNA expression and current estradiol levels or menopausal symptom severity was observed. Bioinformatic analysis of predicted mRNA targets identified significant enrichment of the gonadotropin-releasing hormone (GnRH) receptor pathway, along with related growth factor, immune, and intracellular signaling pathways, with preferential expression in brain-relevant tissues. These findings are consistent with stage-related differences in hormone-sensitive neuronal regulatory processes across the transition.
- Open Access
- 25 February 2026
- Published by Cambridge University Press (CUP) in Development and Psychopathology
- p. 1-11
Sleep regularity, circadian rhythms, and chronotype as mechanisms of risk for affective dysregulation in female adolescents
In a sample of early post-menarchal female adolescents, this study examined sleep regularity in relation to depression symptoms, circadian rhythms, and chronotype preference. Sixty-six female adolescents, aged 11–14 and within fifteen months post-menarche, completed a one-week sleep and circadian rhythm assessment involving self-reported sleep behaviors, 24-h sleep monitoring using wrist actigraphy, and serial cortisol and 6-sulfatoxymelatonin collections for four days. Sleep regularity was operationalized as the probability of being in the same wake/sleep state at any two timepoints 24 h apart (i.e., sleep regularity index (SRI)). Reduced SRI was associated with higher depressive symptoms ( F [1,273] = 18.65, p = < .0001), as were eveningness chronotype ( F [1,273] = 21.13, p = < .0001), sleep duration ( F [1,273] = 6.25, p = .01), and self-reported life stress ( F [1,273] = 22.82, p = < .0001). The interaction between SRI and chronotype was also a predictor of increased depression ( F [1,273] = 18.65, p = < .0001), such that eveningness and low sleep regularity predicted higher scores. Sleep regularity was not significantly associated with cortisol awakening response, cortisol slope, or overnight melatonin levels. Sleep regularity appears linked to altered mood in early post-menarchal girls. Further research linking sleep regularity to physiological processes governing sleep is warranted. Interventions targeting sleep regularity stand to improve mental health outcomes, as well as promote healthy developmental trajectories for affect regulation.
- 25 February 2026
- Published by Cambridge University Press (CUP) in Development and Psychopathology
- p. 1-11
Open AccessSleep regularity, circadian rhythms, and chronotype as mechanisms of risk for affective dysregulation in female adolescents
In a sample of early post-menarchal female adolescents, this study examined sleep regularity in relation to depression symptoms, circadian rhythms, and chronotype preference. Sixty-six female adolescents, aged 11–14 and within fifteen months post-menarche, completed a one-week sleep and circadian rhythm assessment involving self-reported sleep behaviors, 24-h sleep monitoring using wrist actigraphy, and serial cortisol and 6-sulfatoxymelatonin collections for four days. Sleep regularity was operationalized as the probability of being in the same wake/sleep state at any two timepoints 24 h apart (i.e., sleep regularity index (SRI)). Reduced SRI was associated with higher depressive symptoms ( F [1,273] = 18.65, p = < .0001), as were eveningness chronotype ( F [1,273] = 21.13, p = < .0001), sleep duration ( F [1,273] = 6.25, p = .01), and self-reported life stress ( F [1,273] = 22.82, p = < .0001). The interaction between SRI and chronotype was also a predictor of increased depression ( F [1,273] = 18.65, p = < .0001), such that eveningness and low sleep regularity predicted higher scores. Sleep regularity was not significantly associated with cortisol awakening response, cortisol slope, or overnight melatonin levels. Sleep regularity appears linked to altered mood in early post-menarchal girls. Further research linking sleep regularity to physiological processes governing sleep is warranted. Interventions targeting sleep regularity stand to improve mental health outcomes, as well as promote healthy developmental trajectories for affect regulation.
- Open Access
Optimal Frequency for Seizure Induction with Electroconvulsive Therapy and Magnetic Seizure Therapy
Electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) are effective in the treatment of medication-resistant depression. Determining the stimulus frequency resulting in the lowest seizure threshold could produce fewer adverse effects by reducing the overall stimulus intensity. To determine the optimal frequency for seizure induction, four male rhesus macaques were titrated with an increasing number of pulses at fixed frequencies ranging from 5 to 240 pulses per second (pps) using ultrabrief-pulse right-unilateral ECT and circular-coil-on-vertex MST. The seizure threshold dependence on stimulus frequency was similar for ECT and MST. While higher frequencies required progressively shorter trains to induce a seizure, the middle frequency range was associated with the fewest pulses (and hence the least charge and energy), with a minimum at 16 pps and similarly low thresholds for 10 and 25 pps. The number of pulses at seizure threshold increased markedly at lower and higher frequencies. The lowest stimulus frequencies, 5 and 10 pps, were associated with the greatest ictal power measured by electroencephalography. While this study did not assess efficacy or side effects, the results highlight the significance of stimulus frequency for seizure induction, suggest efficient titration schedules that minimize exposure to the electrical stimulus, and can inform studies to assess the impact on clinical outcomes.
Open AccessOptimal Frequency for Seizure Induction with Electroconvulsive Therapy and Magnetic Seizure Therapy
Electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) are effective in the treatment of medication-resistant depression. Determining the stimulus frequency resulting in the lowest seizure threshold could produce fewer adverse effects by reducing the overall stimulus intensity. To determine the optimal frequency for seizure induction, four male rhesus macaques were titrated with an increasing number of pulses at fixed frequencies ranging from 5 to 240 pulses per second (pps) using ultrabrief-pulse right-unilateral ECT and circular-coil-on-vertex MST. The seizure threshold dependence on stimulus frequency was similar for ECT and MST. While higher frequencies required progressively shorter trains to induce a seizure, the middle frequency range was associated with the fewest pulses (and hence the least charge and energy), with a minimum at 16 pps and similarly low thresholds for 10 and 25 pps. The number of pulses at seizure threshold increased markedly at lower and higher frequencies. The lowest stimulus frequencies, 5 and 10 pps, were associated with the greatest ictal power measured by electroencephalography. While this study did not assess efficacy or side effects, the results highlight the significance of stimulus frequency for seizure induction, suggest efficient titration schedules that minimize exposure to the electrical stimulus, and can inform studies to assess the impact on clinical outcomes.
- 5 August 2023
- Published by Springer Nature in CNS Drugs
- Vol. 37 (8) , 679-693
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder
Premenstrual dysphoric disorder (PMDD) is characterized by the predictable onset of mood and physical symptoms secondary to gonadal steroid fluctuation during the luteal phase of the menstrual cycle. Although menstrual-related affective dysfunction is responsible for considerable functional impairment and reduction in quality of life worldwide, currently approved treatments for PMDD are suboptimal in their effectiveness. Research over the past two decades has suggested that the interaction between allopregnanolone, a neurosteroid derivative of progesterone, and the gamma-aminobutyric acid (GABA) system represents an important relationship underlying symptom genesis in reproductive-related mood disorders, including PMDD. The objective of this narrative review is to discuss the plausible link between changes in GABAergic transmission secondary to the fluctuation of allopregnanolone during the luteal phase and mood impairment in susceptible individuals. As part of this discussion, we explore promising findings from early clinical trials of several compounds that stabilize allopregnanolone signaling during the luteal phase, including dutasteride, a 5-alpha reductase inhibitor; isoallopregnanolone, a GABA-A modulating steroid antagonist; and ulipristal acetate, a selective progesterone receptor modulator. We then reflect on the implications of these therapeutic advances, including how they may promote our knowledge of affective regulation more generally. We conclude that these and other studies of PMDD may yield critical insight into the etiopathogenesis of affective disorders, considering that (1) symptoms in PMDD have a predictable onset and offset, allowing for examination of affective state kinetics, and (2) GABAergic interventions in PMDD can be used to better understand the relationship between mood states, network regulation, and the balance between excitatory and inhibitory signaling in the brain.
- 5 August 2023
- Published by Springer Nature in CNS Drugs
- Vol. 37 (8) , 679-693
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder
Premenstrual dysphoric disorder (PMDD) is characterized by the predictable onset of mood and physical symptoms secondary to gonadal steroid fluctuation during the luteal phase of the menstrual cycle. Although menstrual-related affective dysfunction is responsible for considerable functional impairment and reduction in quality of life worldwide, currently approved treatments for PMDD are suboptimal in their effectiveness. Research over the past two decades has suggested that the interaction between allopregnanolone, a neurosteroid derivative of progesterone, and the gamma-aminobutyric acid (GABA) system represents an important relationship underlying symptom genesis in reproductive-related mood disorders, including PMDD. The objective of this narrative review is to discuss the plausible link between changes in GABAergic transmission secondary to the fluctuation of allopregnanolone during the luteal phase and mood impairment in susceptible individuals. As part of this discussion, we explore promising findings from early clinical trials of several compounds that stabilize allopregnanolone signaling during the luteal phase, including dutasteride, a 5-alpha reductase inhibitor; isoallopregnanolone, a GABA-A modulating steroid antagonist; and ulipristal acetate, a selective progesterone receptor modulator. We then reflect on the implications of these therapeutic advances, including how they may promote our knowledge of affective regulation more generally. We conclude that these and other studies of PMDD may yield critical insight into the etiopathogenesis of affective disorders, considering that (1) symptoms in PMDD have a predictable onset and offset, allowing for examination of affective state kinetics, and (2) GABAergic interventions in PMDD can be used to better understand the relationship between mood states, network regulation, and the balance between excitatory and inhibitory signaling in the brain.
- Open Access
- 18 October 2021
- Published by Springer Nature in Biology of Sex Differences
- Vol. 12 (1) , 1-21
In search of sex-related mediators of affective illness
Sex differences in the rates of affective disorders have been recognized for decades. Studies of physiologic sex-related differences in animals and humans, however, have generally yielded little in terms of explaining these differences. Furthermore, the significance of these findings is difficult to interpret given the dynamic, integrative, and highly context-dependent nature of human physiology. In this article, we provide an overview of the current literature on sex differences as they relate to mood disorders, organizing existing findings into five levels at which sex differences conceivably influence physiology relevant to affective states. These levels include the following: brain structure, network connectivity, signal transduction, transcription/translation, and epigenesis. We then evaluate the importance and limitations of this body of work, as well as offer perspectives on the future of research into sex differences. In creating this overview, we attempt to bring perspective to a body of research that is complex, poorly synthesized, and far from complete, as well as provide a theoretical framework for thinking about the role that sex differences ultimately play in affective regulation. Despite the overall gaps regarding both the underlying pathogenesis of affective illness and the role of sex-related factors in the development of affective disorders, it is evident that sex should be considered as an important contributor to alterations in neural function giving rise to susceptibility to and expression of depression.
- 18 October 2021
- Published by Springer Nature in Biology of Sex Differences
- Vol. 12 (1) , 1-21
Open AccessIn search of sex-related mediators of affective illness
Sex differences in the rates of affective disorders have been recognized for decades. Studies of physiologic sex-related differences in animals and humans, however, have generally yielded little in terms of explaining these differences. Furthermore, the significance of these findings is difficult to interpret given the dynamic, integrative, and highly context-dependent nature of human physiology. In this article, we provide an overview of the current literature on sex differences as they relate to mood disorders, organizing existing findings into five levels at which sex differences conceivably influence physiology relevant to affective states. These levels include the following: brain structure, network connectivity, signal transduction, transcription/translation, and epigenesis. We then evaluate the importance and limitations of this body of work, as well as offer perspectives on the future of research into sex differences. In creating this overview, we attempt to bring perspective to a body of research that is complex, poorly synthesized, and far from complete, as well as provide a theoretical framework for thinking about the role that sex differences ultimately play in affective regulation. Despite the overall gaps regarding both the underlying pathogenesis of affective illness and the role of sex-related factors in the development of affective disorders, it is evident that sex should be considered as an important contributor to alterations in neural function giving rise to susceptibility to and expression of depression.